|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Alnylam Pharmaceuticals
| | | Phone: | (617) 551-8200 | Fax: | (617) 551-8101 | Year Established: | 2002 | Ticker: | ALNY | Exchange: | NASDAQ | Main Contact: | Barry Greene, President | | Other Contacts: | Laurie Keating, JD, Senior VP & General Counsel Manmeet Soni, CFO Akshay Vaishnaw, MD, PhD, President, R&D Jing L. Marantz, M.D., Ph.D., Senior VP, Head of Medical Affairs Masako Nakamura, Senior VP, Head of Asia Pushkal Garg, MD,, CMO Yvonne Greenstreet, COO John Maraganore, Ph.D, CEO
| | Company Description | Alnylam Pharmaceuticals is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are in late-stage development or will be in 2017. | |
|
|
|
|
|